It was great news that the recent report from Decision Resources highlighted Lupuzor (owned by ImmuPharma) to potentially have substantial benefits over existing therapies.
Just to clarify ..ImmuPharma issued its Preliminary Results yesterday. You can get the full report on its website.
But key highlights confirm that ImmuPharma is in discussions with partners so that it can commence the pivotal Phase III trial as soon as possible. Watch this space!!